Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM

Published byThomasine Sanders Modified over 6 years ago

Similar presentations

Presentation on theme: "Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM"— Presentation transcript:

1 Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM
Percentage of CD146+ cells (%) Passage number after cell sorting

2 Supplementary Figure 2. H&E INI1 ⅰ ii ⅱ ⅲ ⅳ ⅳ ⅴ ⅵ

3 Supplementary Figure 3. CD146 MP- MRT-AN KP- MRT-RY CD34/CD45/CD31
MRT-YM CD34/CD45/CD31 CD146 First transplantation Second transplantation Third transplantation MP- MRT-AN Supplementary Figure 3. 66.1% 99.0% 99.8% 72.6% 91.7% 97.1% 58.4% 95.0% 99.1%

4 Supplementary Figure 4. A B C D E CD146 Hoechst33342 Merged kDa 250 -
Pre-immune serum Antiserum against CD146 CD146 Hoechst33342 Merged B C kDa 250 - 150 - 100 - 75 - Scramble shRNA CD146 shRNA#2 CD146 β-actin CD146+ cells (KP-MRT-NS) HEK293 CD146− cells (KP-MRT-NS) D E Viable cell (O.D. 450nm) NS Viable cell (O.D. 450nm) NS Hours Hours

5 Days after cell injection
Supplementary Figure 5. A B * Percentage of apoptotic cells (%) Control 10% Rabbit serum Anti-CD146 antiserum * Hours Viable cell (O.D. 450nm) C Days after cell injection D Volume of tumor (mm3) NS * * control 10% Rabbit serum 10% Anti-CD146 antiserum E F * Weight of tumor (mg) PBS Rabbit IgG Anti-CD146 Ab PBS Normal rabbit IgG Anti-CD146　Ab

6 Supplementary Figure 6. A B p-Akt (Ser473) Akt β-actin 10% Rabbit
Scramble shRNA CD146 shRNA#1 CD146 shRNA#2 10% Rabbit serum 10% Anti-CD146 antiserum B p-p38 MAPK (Thr180/Try182) p38　MAPK p-Erk (Thr202/Tyr204) Erk β-actin Scramble shRNA CD146 shRNA#1 CD146 shRNA#2 10% Rabbit serum 10% Anti-CD146 antiserum

7 Supplementary Figure 7. A B C D * * * * * * * * * * * * * * * * * * *
Viable cell (O.D. 450nm) * Viable cell (O.D. 450nm) * * * * * * * * * * * * * * * Hours Hours C D NS * NS * Percentage of apoptotic cells (%) Percentage of Ki-67 positive cells (%) DMSO Rapamycin　 Ku DMSO Rapamycin　 Ku

8 Supplementary Figure 8. A B * C D * E F * * * Hours YM/pFN28A YM/CD146
HaloTag-CD146 Number of spheres/10000 cells β-actin YM /pFN28A YM /CD146 YM/pFN28A YM/CD146 C D * * * Percentage of apoptotic cells (%) Viable cell (O.D. 450nm) * YM/pFN28A YM/CD146 Hours E F NS p-Akt (Ser473) Akt Percentage of Ki-67 positive cells (%) β-actin YM /pFN28A YM /CD146 YM/pFN28A YM/CD146

9 Supplementary Figure 9. A B C D * * NS HEK/pFN28A HEK/CD146 HEK/pFN28A
Viable cell (O.D. 450nm) Hours * CD146 HaloTag-CD146 β-actin HEK/ pFN28A HEK/ CD146 C D * NS Percentage of Ki-67 positive cells (%) Percentage of apoptotic cells (%) HEK/pFN28A HEK/CD146 HEK/pFN28A HEK/CD146

10 Supplementary Figure 10. A * * * * * B * * * * * * *
Volume of tumor (mm3) * * * * * B Volume of tumor (mm3) * * * * * * *

11 Supplementary Figure 11. A B C KP-MRT-NS MP-MRT-AN KP-MRT-NS MP-MRT-AN
Normal rabbit IgG Anti-CD146 Ab KP-MRT-NS MP-MRT-AN B KP-MRT-NS MP-MRT-AN Normal rabbit IgG Anti-CD146 Ab C Vessel number/mm3 KP-MRT-NS Normal rabbit IgG Anti-CD146 Ab NS MP-MRT-AN NS Vessel number/mm3 Normal rabbit IgG Anti-CD146 Ab

12 Days after cell injection
Supplementary Figure 12. A Days after cell injection Volume of tumor (mm3) * * * B * Weight of tumor (mg) Scramble shRNA CD146 shRNA#1 shRNA#2 C Scramble shRNA CD146 shRNA#1 CD146 shRNA#2

13 Supplementary Figure 13. ⅰ ⅱ ⅲ ⅳ ⅴ ⅵ H&E INI1 CD146 Patient #11
(relapse)

Download ppt "Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM"

Similar presentations

A b Supp. Figure 1: Anoikis-resistance of MDA-MB-231 is dependent on PI3Kγ (a) Cells were prevented from attaching for 48 hours in the presence of DMSO,

A b Supp. Figure 1: Anoikis-resistance of MDA-MB-231 is dependent on PI3Kγ (a) Cells were prevented from attaching for 48 hours in the presence of DMSO,
Counts TLR3-PE 100 80 60 40 20 0 Counts TLR8-PE 100 80 60 40 20 0 Counts TLR9-PE 100 80 60 40 20 0 C AB Supplemental Figure 1.

Counts TLR3-PE Counts TLR8-PE Counts TLR9-PE C AB Supplemental Figure 1.
P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt.

P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt.
Serum dilution OD 405 nm PNAG CP5 CP8 AB C Supplemental Figure 1: ELISA analysis of IgG antibody binding in the pre-immune sera of the 9 groups of mice.

Serum dilution OD 405 nm PNAG CP5 CP8 AB C Supplemental Figure 1: ELISA analysis of IgG antibody binding in the pre-immune sera of the 9 groups of mice.
Herceptin + 17-AAG Combination BT-474 Tumors

Herceptin + 17-AAG Combination BT-474 Tumors
Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.

Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.
Vijaya Ramachandran Fig S1 D C Supplementary Figures Invasion Apoptosis A Proliferation BxPC3 0 100 200 300 400 500 % of Viable Cells  AGR2(nM) 0 10 100.

Vijaya Ramachandran Fig S1 D C Supplementary Figures Invasion Apoptosis A Proliferation BxPC % of Viable Cells  AGR2(nM)
Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure1 0 0.03 0.3 3 30 (µM) 120 100 80 60 40 20 0 Penetratin control % of control 0 0.03 0.3 3 30 (µM) 120 100.

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)
Shimura Supplemental Figure 1

Shimura Supplemental Figure 1
Training Set Clinicopathological parameters of the training set

Training Set Clinicopathological parameters of the training set
Supplementary Figure 1. Generation of hepatocyte-specific A20 knockout mice. Targeting scheme. Diagram showing the LoxP-flanked (Floxed) and the deleted.

Supplementary Figure 1. Generation of hepatocyte-specific A20 knockout mice. Targeting scheme. Diagram showing the LoxP-flanked (Floxed) and the deleted.
Supplementary figures

Supplementary figures
Neal et al.Supplementary Figure S1

Neal et al.Supplementary Figure S1
Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.
Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.
A Untreated mM maphos, 48h 20 mM maphos, 48h 50 mM maphos, 48hh B

A Untreated mM maphos, 48h 20 mM maphos, 48h 50 mM maphos, 48hh B
Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes
Covariate AD N (%) SCC N (%) p-values Sex 63/63 96/96 0.097 M

Covariate AD N (%) SCC N (%) p-values Sex 63/63 96/ M
Volume 81, Issue 2, Pages (January 2012)

Volume 81, Issue 2, Pages (January 2012)
Supplementary Table 1 Akt2 is required for NNK-induced lung tumorigenesis but not for urethane-induced lung tumorigenesis while Akt3 may act as a tumor.

Supplementary Table 1 Akt2 is required for NNK-induced lung tumorigenesis but not for urethane-induced lung tumorigenesis while Akt3 may act as a tumor.

Similar presentations

Ads by Google